Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.41 |
| ▸ | TEK | Q02763 | 4/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.40 |
| ▸ | EGFR | P00533 | 6/20 | 0.38 |
| ▸ | BRAF | P15056 | 4/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3830032 | 0.88 | KDR (0.39) | KDRTEKMAPK14EGFRBRAF | |
| SCHEMBL3823908 | 0.88 | KDR (0.40) | KDRTEKMAPK14EGFRBRAF | |
| SCHEMBL3829069 | 0.79 | CYP1A2 (0.50) | MAPK14EGFRBRAF | |
| SCHEMBL1265068 | 0.78 | TEK (0.65) | KDRTEKMAPK14BRAFLCK | |
| SCHEMBL20865561 | 0.70 | ALDH1A1 (0.56) | CA12CA1CA9 | |
| SCHEMBL3829573 | 0.69 | KDR (0.68) | KDRTEKMAPK14BRAFLCK | |
| SCHEMBL3828363 | 0.67 | KDR (0.66) | KDRTEKMAPK14BRAFLCK | |
| SCHEMBL31173043 | 0.67 | CA12 (0.52) | CA12CA1CA9 | |
| SCHEMBL23265149 | 0.67 | ABL1 (0.75) | MAPK14EGFRBRAF | |
| SCHEMBL29873323 | 0.67 | ABL1 (0.75) | MAPK14EGFRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069327-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069327-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | SRC, BMX, FYN | KDR 95/4885TEK 375/4885MAPK14 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.